More research is needed, but things look promising
Due to the fact that the study was limited in patient population, it remains unclear as to whether this type of treatment would prove to be successful in other individuals suffering from IBD. “It's not definitive proof that the agent made him better. It's just suggestive,” said Joel Weinstock, a biomedical researcher at Tufts University. “The worms apparently have several tricks up their sleeve, so to speak, for modulating and regulating the immune system. Interleukin-22 hasn't been on the radar screen,” he added.